Evaluation of the Value of <scp>d</scp>-Dimer, P-Selectin, and Platelet Count for Prediction of Portal Vein Thrombosis After Devascularization

Yang, Fei; Zong, Guanghua; Chen, Jian; Liu, Renmin

doi:10.1177/1076029615569273

Cited by 18 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The platelet size, measured as mean platelet volume (MPV), is a marker of platelet reactivity 5,6 , where larger platelets are hemostatically more reactive than normal sized platelets 1,5 . The association was demonstrated with platelet activity indicators, including the expression of glycoprotein Ib, glycoprotein receptor IIb/IIIa and the expression of higher levels of P-selectin 6,7 .…”

mentioning

confidence: 89%

Mean platelet volume as a prognostic factor for venous thromboembolic disease

et al. 2019

View full text Add to dashboard Cite

Background: Mean platelet volume (MPV) is a risk factor for cardiovascular and inflammatory diseases. Aim: To evaluate the association between high MPV and 90-day mortality after an episode of venous thromboembolism (VTE). Material and Methods: Retrospective cohort of 594 patients with a median age of 73 years (58% women) with a first episode VTE, included in an institutional Thromboembolic Disease registry between 2014 and 2015. MPV values were obtained from the automated blood cell count measured at the moment of VTE diagnosis. Volumes ≥ 11 fL were classified as high. All patients were followed for 90 days to assess survival. Results: The main comorbidities were cancer in 221 patients (37%), sepsis in 172 (29%) and coronary artery disease in 107 (18%). Median MPV was 8 fl (8-9), brain natriuretic peptide 2,000 pg/ml (1,025-3,900) and troponin 40 pg/ml (19.5-75). Overall mortality was 20% (121/594) during the 90 days of follow-up. Thirty three deaths occurred within 7 days and 43 within the first month. The loss of patients from follow-up was 5% (28/594) at 90 days. Mortality among patients with high MP was 36% (23/63). The crude mortality hazard ratio (HR) for high MPV was 2.2 (95% confidence intervals (CI) 1.4-3.5).When adjusted for sepsis, oncological disease, heart disease, kidney failure and surgery, the mortality HR of high MPV was 2.4 (CI95% 1.5-3.9) in the VTE group, 2.3 (CI95% 1.5-4.4) in the deep venous thrombosis group, and 2.9 (CI95% 1.6-5.6) in the pulmonary embolism group. Conclusions: High MPV is an independent risk factor for mortality following an episode of VTE.

show abstract

mentioning

confidence: 89%

Mean platelet volume as a prognostic factor for venous thromboembolic disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…RT-qPCR analyses were performed to detect the mRNA expression level of P-selectin, a biomarker of PVT (20) in rats of the model and control groups 24 h following surgery. Total RNA was extracted from blood samples using RNA Extraction kit and reverse transcribed into cDNA using the First Strand cDNA Synthesis kit (both Beyotime Institute of Biotechnology, Shanghai, China).…”

Section: Methodsmentioning

confidence: 99%

The inhibitory role of recombinant P‑selectin glycoprotein ligand immunoglobulin G on portal vein thrombosis based on a novel rat model

et al. 2019

View full text Add to dashboard Cite

The current study aimed to reveal a novel method for constructing a portal vein thrombosis (PVT) model in rats and to evaluate the inhibitory role of recombinant P-selectin glycoprotein ligand immunoglobulin G (rPSGL-Ig) on the formation of PVT. The PVT model was constructed in rats through intermittent portal vein obstruction (IPVO) combined with endangium destruction. A total of 4 mg/kg rPSGL-Ig was intraperitoneally pre-injected into rats 1 h prior to model construction. Changes in the thrombus size and vessel diameter were observed by B-scan ultrasonography. Histopathological changes in the portal vein, central hepatic vein and vasa intestini tenuis were observed using hematoxylin and eosin staining. Additionally, histopathological changes in the portal vein were observed by transmission electron microscopy. A total of 8 mg/kg rPSGL-Ig or 2×10 4 U/kg urokinase were used to compare the thrombolytic effects and thrombus sizes. The PVT model was successfully constructed in rats, and exhibited a significantly greater thrombus size and vessel diameter compared with the control group (P<0.05). Intervention with rPSGL-Ig significantly inhibited the formation of PVT, and resulted in a significantly lower thrombus size and vessel diameter compared with the model group (P<0.05). Additionally, histopathological changes in the portal vein, central hepatic vein and vasa intestini tenuis in PVT rats were considerably reversed following the intervention with rPSGL-Ig. rPSGL-Ig demonstrated a lower thrombolytic effect compared with that of URO. IPVO combined with endangium destruction effectively constructed a PVT model in rats. rPSGL-Ig effectively prevented PVT in rats. rPSGL-Ig may be used in future studies for the treatment of patients with PVT.

show abstract

“…1, while the citations of the excluded articles are available upon request). Finally, 12 studies were included in this systematic review [21][22][23][24][25][26][27][28][29][30][31][32], since 2 patients cohorts were reported in more than one publication [33,34]. No additional studies were identified from the reference lists of the 14 retrieved reports, from 2 systematic review published on this topic [10,35] and from searching into the grey literature.…”

Section: Study Identification and Selectionmentioning

confidence: 99%

“…In fact, 7 studies enrolled patients undergoing surgical procedures (e.g. splenectomy, hepatectomy, or gastroesophageal devascularisation) [22][23][24]27,[30][31][32], often in combination with other risk factors (such as liver cirrhosis [23,24,27,30,31] or HCC [32]); 4 studies enrolled patients with liver cirrhosis only [21,25,26,28] and one study enrolled patients with HCC only [29]. In addition, 9 studies evaluated patients with different degree of liver dysfunction, as expressed by Child-Pugh classes A, B or C [21,[23][24][25][26]28,[30][31][32]; however, separate sensitivity and specificity data were available only in 7 of them [21,23,25,26,28,31,32].…”

Section: Study Characteristicsmentioning

confidence: 99%

Diagnostic accuracy of D-dimer in patients at high-risk for splanchnic vein thrombosis: A systematic review and meta-analysis

Riva

Attard

Vella

et al. 2021

Thrombosis Research

View full text Add to dashboard Cite

Background: D-dimer is included in the diagnostic algorithm for deep vein thrombosis and pulmonary embolism. However, its role in the diagnosis of splanchnic vein thrombosis (SVT) is still controversial. The aim of this study was to evaluate the diagnostic accuracy of D-dimer for SVT. Methods: We performed a systematic review of the literature with meta-analysis (PROSPERO protocol registration number: CRD42020184300). The electronic databases MEDLINE, EMBASE, and CENTRAL were searched from inception to March 2021 week 4. Studies which evaluated D-dimer accuracy for SVT in any category of patients were selected. The index test was any D-dimer assay; the reference standard was any radiological imaging. The QUADAS-2 checklist was used for the risk of bias assessment. A bivariate random-effects regression model was used to calculate summary estimates of sensitivity and specificity. Results: 12 studies (with a total of 1298 patients) evaluating the accuracy of D-dimer in patients at high risk of SVT (surgical patients, patients with liver cirrhosis or hepatocellular carcinoma) were included. None of the included studies was at low risk of bias. The weighted mean prevalence of SVT was 33.4% (95% CI, 22.5-45.2%, I 2 = 94.8%). D-dimer accuracy was expressed by sensitivity 96% (95% CI, 72-100%); specificity 25% (95% CI, 5-67%); positive likelihood ratio 1.3 (95% CI, 0.9-1.9); negative likelihood ratio 0.16 (95% CI, 0.03-0.84); area under the ROC curve 0.80 (95% CI, 0.76-0.83). Conclusions: D-dimer seems to have high sensitivity in the diagnosis of patients at high-risk for SVT. However, there is a strong need for more robust evidence on this topic.

show abstract

Evaluation of the Value of d-Dimer, P-Selectin, and Platelet Count for Prediction of Portal Vein Thrombosis After Devascularization

Abstract: The level of d-dimer, P-selectin, and platelet count might be good candidate predictive markers for PVT in patients with cirrhotic PHT after devascularization. The combined test of the 3 markers can increase the value of prediction.

Cited by 18 publications

References 23 publications

Mean platelet volume as a prognostic factor for venous thromboembolic disease

Mean platelet volume as a prognostic factor for venous thromboembolic disease

The inhibitory role of recombinant P‑selectin glycoprotein ligand immunoglobulin G on portal vein thrombosis based on a novel rat model

Diagnostic accuracy of D-dimer in patients at high-risk for splanchnic vein thrombosis: A systematic review and meta-analysis

Contact Info

Product

Resources

About